Literature DB >> 9989618

Anti-GD1a antibody is associated with axonal but not demyelinating forms of Guillain-Barré syndrome.

T W Ho1, H J Willison, I Nachamkin, C Y Li, J Veitch, H Ung, G R Wang, R C Liu, D R Cornblath, A K Asbury, J W Griffin, G M McKhann.   

Abstract

Immunopathological studies suggest that the target of immune attack is different in the subtypes of Guillain-Barré syndrome (GBS). In acute motor axonal neuropathy (AMAN), the attack appears directed against the axolemma and nodes of Ranvier. In acute inflammatory demyelinating polyneuropathy (AIDP), the attack appears directed against a component of the Schwann cell. However, the nature of the antigenic targets is still not clear. We prospectively studied 138 Chinese GBS patients and found that IgG anti-GD1a antibodies were closely associated with AMAN but not AIDP. With a cutoff titer of greater than 1:100, 60% of AMAN versus 4% of AIDP patients had IgG anti-GD1a antibodies; with a cutoff titer of greater than 1:1,000, 24% of AMAN patients and none of the AIDP patients had IgG anti-GD1a antibodies. In contrast, low levels of IgG anti-GM1 antibodies (> 1:100) were detected in both the AMAN and the AIDP forms (57% vs 35%, NS). High titers of IgG anti-GM1 (>1:1,000) were more common in the AMAN form (24% vs 8%, NS). Serological evidence of recent Campylobacter infection was detected in 81% of AMAN and 50% of AIDP patients, and anti-ganglioside antibodies were common in both Campylobacter-infected and noninfected patients. Our results suggest that IgG anti-GD1a antibodies may be involved in the pathogenesis of AMAN.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9989618     DOI: 10.1002/1531-8249(199902)45:2<168::aid-ana6>3.0.co;2-6

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  51 in total

Review 1.  Guillain Barré syndrome.

Authors:  J B Winer
Journal:  Mol Pathol       Date:  2001-12

2.  Preceding infections and anti-ganglioside antibody profiles assessed by a dot immunoassay in 306 French Guillain-Barré syndrome patients.

Authors:  Christiane Caudie; Arnaud Quittard Pinon; Didier Taravel; Valérie Sivadon-Tardy; David Orlikowski; Flore Rozenberg; Tarek Sharshar; Jean Claude Raphaël; Jean Louis Gaillard
Journal:  J Neurol       Date:  2011-04-24       Impact factor: 4.849

Review 3.  Progress in inflammatory neuropathy -the legacy of Dr Jack Griffin.

Authors:  Eva L Feldman; Richard A C Hughes; Hugh J Willison
Journal:  Nat Rev Neurol       Date:  2015-10-13       Impact factor: 42.937

Review 4.  Guillain-barré syndrome: modern theories of etiology.

Authors:  Todd A Hardy; Stefan Blum; Pamela A McCombe; Stephen W Reddel
Journal:  Curr Allergy Asthma Rep       Date:  2011-06       Impact factor: 4.806

Review 5.  Guillain-Barré syndrome: a century of progress.

Authors:  John A Goodfellow; Hugh J Willison
Journal:  Nat Rev Neurol       Date:  2016-11-18       Impact factor: 42.937

6.  Miller Fisher syndrome.

Authors:  Suresh Kumar Gupta; Kunal Kishor Jha; Mhd Diaa Chalati; Losan Tareq Alashi
Journal:  BMJ Case Rep       Date:  2016-10-13

Review 7.  Immune-mediated neuropathies.

Authors:  Bernd C Kieseier; Emily K Mathey; Claudia Sommer; Hans-Peter Hartung
Journal:  Nat Rev Dis Primers       Date:  2018-10-11       Impact factor: 52.329

8.  Ganglioside agglutination immunoassay for rapid detection of autoantibodies in immune-mediated neuropathy.

Authors:  A Alaedini; I Wirguin; N Latov
Journal:  J Clin Lab Anal       Date:  2001       Impact factor: 2.352

Review 9.  Quantifying the association between Campylobacter infection and Guillain-Barré syndrome: a systematic review.

Authors:  Kate O Poropatich; Christa L Fischer Walker; Robert E Black
Journal:  J Health Popul Nutr       Date:  2010-12       Impact factor: 2.000

Review 10.  Systematic reviews of treatment for inflammatory demyelinating neuropathy.

Authors:  R A C Hughes
Journal:  J Anat       Date:  2002-04       Impact factor: 2.610

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.